Follow
Mirza MR
Mirza MR
Nordic Society of Gynaecological Oncology
Verified email at regionh.dk
Title
Cited by
Cited by
Year
A phase 3 trial of bevacizumab in ovarian cancer
TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ...
New England Journal of Medicine 365 (26), 2484-2496, 2011
25112011
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ...
New England Journal of Medicine 375 (22), 2154-2164, 2016
23752016
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up
N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ...
International Journal of Gynecologic Cancer 26 (1), 2016
18622016
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ...
Obstetrical & Gynecological Survey 69 (7), 402-404, 2014
16642014
Niraparib in patients with newly diagnosed advanced ovarian cancer
A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ...
New England Journal of Medicine 381 (25), 2391-2402, 2019
16632019
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ...
International Journal of Gynecologic Cancer 31 (1), 2021
12952021
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A Du Bois, J Ledermann, WG McCluggage, ...
Annals of Oncology 30 (5), 672-705, 2019
10272019
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
8802015
Cancer of the corpus uteri
F Amant, MR Mirza, M Koskas, CL Creutzberg
International Journal of Gynecology & Obstetrics 143, 37-50, 2018
3872018
Incorporation of pazopanib in maintenance therapy of ovarian cancer
A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ...
Journal of clinical oncology 32 (30), 3374-3382, 2014
3792014
ESMO-ESGO-ESTRO endometrial consensus conference working group
N Colombo, C Creutzberg, F Amant, T Bosse, A Gonzalez-Martin, ...
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis …, 2016
3102016
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the …
J Pfisterer, B Weber, A Reuss, R Kimmig, A Du Bois, U Wagner, ...
Journal of the National Cancer Institute 98 (15), 1036-1045, 2006
2622006
The forefront of ovarian cancer therapy: update on PARP inhibitors
MR Mirza, RL Coleman, A González-Martín, KN Moore, N Colombo, ...
Annals of Oncology 31 (9), 1148-1159, 2020
2422020
AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer
E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ...
J Clin Oncol 30, 327s, 2012
2382012
Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease
MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza, D Lorusso, AM Oza, ...
Annals of Oncology 28 (4), 727-732, 2017
2352017
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup …
A du Bois, B Weber, J Rochon, W Meier, A Goupil, S Olbricht, JC Barats, ...
Journal of clinical oncology 24 (7), 1127-1135, 2006
2332006
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
A Du Bois, G Kristensen, I Ray-Coquard, A Reuss, S Pignata, N Colombo, ...
The Lancet Oncology 17 (1), 78-89, 2016
2302016
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm …
RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ...
The Lancet Oncology 22 (5), 609-619, 2021
2212021
First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors
ARA Razak, M Mau-Soerensen, NY Gabrail, JF Gerecitano, AF Shields, ...
Journal of Clinical Oncology 34 (34), 4142, 2016
2192016
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
MR Mirza, EĹ Lundqvist, MJ Birrer, RP Christensen, GB Nyvang, ...
The Lancet Oncology 20 (10), 1409-1419, 2019
2132019
The system can't perform the operation now. Try again later.
Articles 1–20